Who founded Actymthera?

Actymthera was founded by Christopher D Thanos in 2017.

Who are Actymthera's investors?

Actymthera's investors include Illumina Ventures.

How much funding has Actymthera raised?

Actymthera has disclosed $25.3M raised across 2 rounds.

Where is Actymthera headquartered?

Actymthera is headquartered in Berkeley, US.

Actymthera

Berkeley, US · Founded 2017 · 1 known investors

Find your way into Actymthera

Paths you didn't know you had: your email and LinkedIn already hold routes to the Actymthera team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Actym Therapeutics engineers bacteria as a delivery system for therapeutics targeting cancer and fibrotic disease. Its approach uses engineered S. Typhimurium to systemically administer and locally produce multiple therapeutic payloads at the disease site to reduce systemic toxicity.

Biotech Healthtech

Founders & leadership

Actymthera was founded in 2017 by Christopher D Thanos.

Christopher D ThanosFounder

Kanad DasNamed on SEC filing

Amit KumarNamed on SEC filing

James HuangNamed on SEC filing

Investors · 1

Illumina Ventureslisted by Illumina VenturesFoster City

How we know: Illumina Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$25.3M disclosed across 2 rounds · 2020–2023

▶$11.2MraisedJul 2023 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Christopher D ThanosExecutive Officer, Director
Benjamin ChenDirector
Ron MazumderDirector
Julie CherringtonDirector
Kanad DasDirector

Offering amount: $27.5M
Amount sold: $11.2M
First sale: Jun 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$14.1MraisedApr 2020 · 28 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Kanad DasDirector
Amit KumarDirector, Promoter
James HuangDirector
Christopher D ThanosExecutive Officer, Director, Promoter

Offering amount: $41.2M
Amount sold: $14.1M
First sale: Mar 2020
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 6

Actuate TherapeuticsActuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a small-molecule GSK-3β inhibitor designed to treat difficult-to-treat cancers including pancreatic, melanoma, lung, and pediatric cancers through intravenous injection and oral tablet formulations. The company is advancing elraglusib in multiple clinical trials, with Phase 2 data in metastatic pancreatic cancer showing improved overall survival when combined with standard chemotherapy.

Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.

AgenusAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.

Context TherapeuticsContext Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors. Its pipeline targets antigens such as Claudin 6, mesothelin, and Nectin-4 to direct the immune system against difficult-to-treat cancers.

SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

IfmtheraIFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer. The company operates through independently financed R&D subsidiaries, each advancing programs aimed at key control nodes of innate immunity such as NLRP3 and cGAS/STING.

Companies working in the same space as Actymthera.

Frequently asked questions

What does Actymthera do?: Actym Therapeutics engineers bacteria as a delivery system for therapeutics targeting cancer and fibrotic disease. Its approach uses engineered S. Typhimurium to systemically administer and locally produce multiple therapeutic payloads at the disease site to reduce systemic toxicity.
Who founded Actymthera?: Actymthera was founded by Christopher D Thanos in 2017.
Who are Actymthera's investors?: Actymthera's investors include Illumina Ventures.
How much funding has Actymthera raised?: Actymthera has disclosed $25.3M raised across 2 rounds.
Where is Actymthera headquartered?: Actymthera is headquartered in Berkeley, US.